Effects of combined estrogen and bazedoxifene (CEB) on depressive symptoms in perimenopause
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.119853 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Erin Bondy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States. Electronic address: Erin_Bo…. Hauptthemen laut MEDLINE: Indoles, Perimenopause, Selective Estrogen Receptor Modulators, Estrogens, Conjugated (USP). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Center for Advancing Translational Sciences, National Institutes of Health, Institute of Clinical and Translational Sciences.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Perimenopause is characterized by ovarian hormone fluctuation and associated with elevated risk for depression. Perimenopausal-onset major depression (PO-MDD) can be alleviated with estrogen treatment. However, due to potential risk for breast and uterine cancer, traditional hormone treatments may not be suitable for some. Conjugated estrogen combined with the selective estrogen receptor modulator (SERM) bazedoxifene (CEB) is a tissue selective estrogen complex (TSEC) used to target hot flashes and postmenopausal osteoporosis. CEB's effect on mood during perimenopause remains understudied. METHODS: In this open-label pilot clinical trial, CEB was administered to perimenopausal women (N = 10) for three weeks with weekly symptom assessments and estradiol measurements. Mixed effects models were used to examine changes in affective and menopausal symptoms. RESULTS: Menopausal symptoms were significantly reduced over the course of treatment, and several depression symptom domains were also reduced (e.g., dysphoria, anhedonia, ill temper, insomnia; all pFDRs < 0.05). DISCUSSION: The current findings suggest that CEB reduces mood and menopausal symptoms without the concurrent risk profile of standard hormonal treatments. Further research is needed to understand potential links with estradiol variability and implications for the further development of treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States. Electronic address: Erin_Bondy@med.unc.edu.
- Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
- Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
- Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States; Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill Sc…
Förderung
- National Center for Advancing Translational Sciences
- National Institutes of Health
- Institute of Clinical and Translational Sciences
- North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill
- Foundation of Hope for Research and Treatment of Mental Illness
Zitieren
APA
Bondy, E., Prim, J., Rubinow, D., Schiff, L., Dichter, G. S., & Schiller, C. E. (2025). Effects of combined estrogen and bazedoxifene (CEB) on depressive symptoms in perimenopause. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119853
Vancouver
Bondy E, Prim J, Rubinow D, Schiff L, Dichter GS, Schiller CE. Effects of combined estrogen and bazedoxifene (CEB) on depressive symptoms in perimenopause. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119853
BibTeX
@article{Bondy2025,
author = {Bondy, Erin and Prim, Julianna and Rubinow, David and Schiff, Lauren and Dichter, Gabriel S and Schiller, Crystal E},
title = {Effects of combined estrogen and bazedoxifene (CEB) on depressive symptoms in perimenopause},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.119853}
}
EUVIMED